To evaluate the effects of TILs on the clinical outcome of patients with bladder cancer, CD4+, CD8+, CD25+, FoxP3+ and CD20+ TILs were analyzed in relation to patients’ death/survival. The gene discussed is FOXP3; the disease is urinary bladder cancer.